Duan Y.,Deparment of Nuclear Medical |
Xu R.-S.,Deparment of Nuclear Medical |
Wu H.-W.,Deparment of Nuclear Medical |
He W.-G.,Deparment of Nuclear Medical |
Shu B.,Deparment of Nuclear Medical
Journal of Sichuan University (Medical Science Edition) | Year: 2011
Objective: To study the influence of 89SrCl2 on CD4+CD25+ regulatory T cells and its Foxp3 mRNA expression in cancer patients with bone metastases. Methods: Peripheral blood samples were collected from 57 patients with bone metastases cancer and 25 healthy controls, the amount of CD4+CD25+ regulatory T cells in peripheral blood was determined by flow cytometry, the expression level of Foxp3 mRNA in these regulatory T cells was detected by RT-PCR. Results: The percentage of CD4+CD25+ regulatory T cells in CD4+ cells was (11. 3± 5. 5)% in the patients with bone metastases, which was significantly more than that (5. 6 ± 1. 5)% in healthy control (P<0. 01). After the treatment of 89SrCl2, it was decreased to(10. 4 ± 5. 2)%, and the decrease was statistically significant (P<0. 05). The expression level of Foxp3 mRNA was decreased significantly from 0. 348± 0.028 to 0.296±0. 029 by the treatment of 89SrCl2(P<0. 05). In addition, the amount of CD4 +CD25+T cells in the patients obtaining 89SrCl2 therapeutic effects was (9. 3±4. 2) %, which was lower than that in those patients without effects (12. 9±5. 3)%(P<0. 01). The relative expression level of Foxp3 mRNA was 0. 254±0. 025 in the patients obtaining therapeutic effects, which was also significantly less than that (0. 397±0. 029) in those patients without any effects (P<0. 01). Conclusion: Foxp3 gene play a pivotal role in the regulation of CD4+ CD25+ T cells. The treatment of 89SrCl2 could decrease the amount of CD4 +CD25+T cells and down-regulate Foxp3 mRNA expression of these cells in bone metastases cancer patients.